Janux Therapeutics, Inc.

NasdaqGM:JANX Stok Raporu

Piyasa değeri: US$2.6b

Janux Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Janux Therapeutics CEO'su David Campbell, Jun2017 tarihinde atandı, in görev süresi 7.42 yıldır. in toplam yıllık tazminatı $ 4.19M olup, şirket hissesi ve opsiyonları dahil olmak üzere 14.9% maaş ve 85.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.54% ine doğrudan sahiptir ve bu hisseler $ 14.19M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.3 yıl ve 3.7 yıldır.

Anahtar bilgiler

David Campbell

İcra Kurulu Başkanı

US$4.2m

Toplam tazminat

CEO maaş yüzdesi14.9%
CEO görev süresi7.4yrs
CEO sahipliği0.5%
Yönetim ortalama görev süresi2.3yrs
Yönetim Kurulu ortalama görev süresi3.7yrs

Son yönetim güncellemeleri

Recent updates

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Oct 01
Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Janux Therapeutics: Buoyed By Buyout Speculation

Sep 01

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Jul 01
Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 11

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Feb 27

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Feb 24
Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Dec 29
Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Nov 04
Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

Jul 20
We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 23
A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Feb 09
Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Oct 19
We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Aug 09

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Jun 05
We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Feb 19
Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Nov 03
Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

CEO Tazminat Analizi

David Campbell'un ücretlendirmesi Janux Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$61m

Jun 30 2024n/an/a

-US$44m

Mar 31 2024n/an/a

-US$56m

Dec 31 2023US$4mUS$625k

-US$58m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$67m

Dec 31 2022US$6mUS$550k

-US$63m

Sep 30 2022n/an/a

-US$60m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$8mUS$459k

-US$33m

Sep 30 2021n/an/a

-US$21m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$812kUS$405k

-US$7m

Tazminat ve Piyasa: David 'nin toplam tazminatı ($USD 4.19M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 6.60M ).

Tazminat ve Kazançlar: David 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

David Campbell (64 yo)

7.4yrs

Görev süresi

US$4,193,269

Tazminat

Dr. David Campbell, Ph D serves as President, Chief Executive Officer and Director of Janux Therapeutics, Inc. since inception in June 2017. He founded Janux in 2017 to develop tumor-specific cancer therap...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
David Campbell
President7.4yrsUS$4.19m0.54%
$ 14.2m
Charles Winter
Chief Technical Officer1.8yrsUS$1.61m0.098%
$ 2.6m
Byron Robinson
Chief Strategy Officer2.8yrsUS$1.74m0%
$ 0
Matt Whitmire
Vice President of Financeless than a yearVeri yokVeri yok
Maria Dobek
Principal Accounting Officer & VP of Accountingless than a yearVeri yokVeri yok
Tommy Diraimondo
Chief Scientific Officerless than a yearVeri yok0.19%
$ 4.9m
James Pennington
General Counsel3.3yrsVeri yokVeri yok
Andy Meyer
Chief Business Officer3.7yrsVeri yok0.13%
$ 3.4m

2.3yrs

Ortalama Görev Süresi

47.5yo

Ortalama Yaş

Deneyimli Yönetim: JANX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
David Campbell
President7.4yrsUS$4.19m0.54%
$ 14.2m
Charles Hart
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Vickie Capps
Independent Director3.7yrsUS$173.01k0.13%
$ 3.4m
Ronald Barrett
Chairperson3.2yrsUS$162.69k0%
$ 0
Mark Davis
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Alana McNulty
Independent Director3.2yrsUS$166.57k0%
$ 0
Charles Craik
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Sheila Gujrathi
Director3.7yrsUS$158.01k0.21%
$ 5.7m
Winston Kung
Independent Director2.2yrsUS$164.77k0%
$ 0
Jake Simson
Independent Director3.7yrsUS$172.07k0%
$ 0
Greg Weiss
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Jennifer Maynard
Member of Scientific Advisory Boardno dataVeri yokVeri yok

3.7yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: JANX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.7 yıldır).